Bal Pharma Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Bal Pharma Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Debt, after subtracting cash, is 1.2 times its market value (net debt). Lower than almost all Healthcare companies in India.
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹354 of operating cash. Higher than 93% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹354Over the last 3 years, every ₹100 of reported profit came with ₹354 of operating cash.
Higher than 93% of Healthcare companies in India.
Self-Funding Ratio
1.4×Over the last 3 years its own operating cash covered its investment spending (capex) 1.4 times.
Higher than 54% of Healthcare companies in India.
Cash Locked Ratio
₹35For every ₹100 of sales, ₹35 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹35 tied up three years earlier.
More money tied up than 71% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Less steady than 84% of Healthcare companies in India.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by +0% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
+0% / +20%In 3 years sales changed by +0% while total assets changed by +20%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.2×Debt due within a year is covered 0.2 times by its yearly operating cash.
Lower than 82% of Healthcare companies in India.
Cash Cushion Ratio
1.2× debtDebt, after subtracting cash, is 1.2 times its market value (net debt).
Lower than almost all Healthcare companies in India.
Tangible Assets Ratio
95%Of every ₹100 the company owns, ₹95 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 59% of Healthcare companies in India.
Tangible Net Worth Ratio
79%Of every ₹100 of net worth, ₹79 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 75% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Bal Pharma Limited owes ₹0.78 for every ₹1 it owns. Net profit fell 13% in the year to Mar 2026, and grew 35% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
17.9Investors pay ₹17.9 for every ₹1 of Bal Pharma Limited's yearly profit, lower than 86% of Healthcare companies in India.
P/B ratio
1.57The share price is 1.57 times Bal Pharma Limited's book value per share, lower than 92% of Healthcare companies in India.
Market cap
₹129 CrThe total market value of all of Bal Pharma Limited's shares at today's price (share price × number of shares), smaller than 96% of Healthcare companies in India. PosiCap size class: Micro Cap.
Net worth (book value)
₹82 CrWhat Bal Pharma Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹51.65Net worth divided by the number of shares. The share price of ₹81.09 is 1.6 times this, which is the P/B above.
Return on equity (ROE)
8.8%Bal Pharma Limited earned 8.8% on its shareholders' money over the last year, lower than 72% of Healthcare companies in India.
Owes vs Owns
0.78×Bal Pharma Limited owes ₹0.78 for every ₹1 it owns (moderate), higher than 98% of Healthcare companies in India.
Dividend yield
1.29%Bal Pharma Limited pays 1.29% of its share price as dividends a year, higher than 86% of dividend-paying Healthcare companies in India.
Revenue growth
+3%Revenue rose 3% in the year to Mar 2026, and grew 0% a year on average over 3 years.
Profit growth
-13%Net profit fell 13% in the year to Mar 2026, and grew 35% a year on average over 3 years.
Profit margin
2.1%Bal Pharma Limited keeps ₹2 of every ₹100 of revenue as net profit.
Cash quality
4.9×Cash from Bal Pharma Limited's business was 4.9× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
1.5×Bal Pharma Limited's operating profit covered its interest costs 1.5 times in the year to Mar 2026.
Cash vs debt
Net debtBal Pharma Limited had ₹157 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Bal Pharma Limited's P/E ratio?
Investors pay ₹17.9 for every ₹1 of Bal Pharma Limited's yearly profit, lower than 86% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Bal Pharma Limited: ₹129 Cr ÷ ₹82 Cr (31 Mar 2026) = 1.6.
What is Bal Pharma Limited's return on equity?
Bal Pharma Limited earned 8.8% on its shareholders' money over the last year, lower than 72% of Healthcare companies in India.
How much does Bal Pharma Limited owe compared with what it owns?
Bal Pharma Limited owes ₹0.78 for every ₹1 it owns (moderate), higher than 98% of Healthcare companies in India.
Does Bal Pharma Limited pay a dividend?
Yes. Bal Pharma Limited pays 1.29% of its share price as dividends a year, higher than 86% of dividend-paying Healthcare companies in India.
Is Bal Pharma Limited's revenue growing?
Revenue rose 3% in the year to Mar 2026, and grew 0% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.